JNJ · News · 20260908N
Neuropsychiatry Pipeline Progress
JOHNSON & JOHNSON · 2026-09-08 · Importance 23 · Surprise 24 · In source text
Johnson & Johnson announced that 24 clinical-data and real-world-evidence abstracts from its neuropsychiatry portfolio will be presented at the Psych Congress Annual Meeting in New Orleans from September 15-19, 2026. The program includes pivotal Phase 3 CAPLYTA data in adults with bipolar mania, new SPRAVATO analyses focused on anhedonia, and Phase 3 seltorexant data as adjunctive treatment for major depressive disorder with insomnia. Additional presentations will cover schizophrenia-related hospitalizations and treatment satisfaction for paliperidone palmitate injectables.
Key facts
- Johnson & Johnson will present 24 abstracts featuring clinical data and real-world evidence across the neuropsychiatry portfolio at the 2026 Psych Congress Annual Meeting (September 15-19, New Orleans, LA). source
- The first presentation of pivotal Phase 3 CAPLYTA data in adults with bipolar mania was announced by Johnson & Johnson as part of its Psych Congress materials. source
- Johnson & Johnson will present Phase 3 data for seltorexant as an adjunctive treatment for MDD with insomnia at Psych Congress 2026. source
- Johnson & Johnson will present new SPRAVATO analyses and schizophrenia research at Psych Congress 2026. source
- Johnson & Johnson will share real-world studies on schizophrenia-related hospitalizations and treatment satisfaction for its paliperidone palmitate injectable portfolio at Psych Congress 2026. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | contingent | — | The first presentation of pivotal Phase 3 CAPLYTA data in adults with bipolar mania was announced by Johnson & Johnson as part of its… |
| revenue | positive | contingent | — | Johnson & Johnson will present Phase 3 data for seltorexant as an adjunctive treatment for MDD with insomnia at Psych Congress 2026. |